Aligos therapeutics expands collaboration with merck to develop oligonucleotide therapies for nash

South san francisco, calif., jan. 11, 2022 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expanded its ongoing collaboration agreement with merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (nash).
ALGS Ratings Summary
ALGS Quant Ranking